bpc-157 fda advisory committee votes to add popular peptide to drug compounding list FDA panel votes to ease

We noted in the Final Decision Memorandum, there is insufficient evidence on the test characteristics and performance of screening CTC in Medicare aged individuals and that the evidence is not sufficient to conclude that screening CTC improves health benefits for asymptomatic, average risk Medicare beneficiaries. [713] At that time, the October 2008 USPSTF revised Final Recommendation Statement read, [t]he USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer

This isn't a place for improvisation

This stack builds on foundational regenerative compounds with the addition of a copper-binding peptide commonly studied in advanced research settings

Maybe the answer lies somewhere in the middle - should you use AHK-Cu and minoxidil together for the best of both worlds